skip to main content

H.R. 2732 (116th): LABEL Opioids Act

The text of the bill below is as of May 14, 2019 (Introduced). The bill was not enacted into law.



1st Session

H. R. 2732


May 14, 2019

(for himself and Mr. McAdams) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned


To amend the Controlled Substances Act to require warning labels for prescription opioids, and for other purposes.


Short title

This Act may be cited as the Lessening Addiction By Enhancing Labeling Opioids Act of 2019 or the LABEL Opioids Act.




In general

Section 305(c) of the Controlled Substances Act (21 U.S.C. 825(c)) is amended—


by inserting (1) before The Secretary; and


by adding at the end the following:


The label of any container or package containing an opioid or opiate listed in schedule II, III, IV, or V shall, when dispensed (other than administered) to or for a patient, contain a clear, concise warning, in a manner specified by the Secretary by regulation, that the opioids or opiates dispensed can cause dependence, addiction, and overdose.






The Secretary of Health and Human Services shall prescribe regulations under section 503(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)) to implement the amendment made by subsection (a) and such regulations shall be effective not later than 2 years after the date of enactment of this Act.


Interim rules

The Secretary of Health and Human Services may issue the regulations required under paragraph (1) by interim rule to the extent necessary to comply with the timing requirement in paragraph (1).